在复发或巩固治疗中接受本妥昔单抗维泊妥珠单抗治疗的霍奇金淋巴瘤患者中，与 FDG-PET-CT 缓解相关的结局。

Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.

机构信息

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel-Aviv university, Tel-Aviv, Israel; The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.

出版信息

Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):e929-e937. doi: 10.1016/j.clml.2021.07.006. Epub 2021 Jul 12.

DOI:10.1016/j.clml.2021.07.006

PMID:34366266

Abstract

BACKGROUND

Brentuximab-vedotin (BV) monotherapy has shown high efficacy in heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma (HL) after high-dose chemotherapy or autologous stem cell transplantation (ASCT). We retrospectively analyzed the outcomes of treatment with BV of HL patients and examined the predictive ability of PET-CT for response in this setting.

PATIENTS AND METHODS

Records of 49 HL patients (median age, 39 years, 55% male) treated with BV for relapse (71.4%) or consolidation (28.6%) post-ASCT were analyzed. Patients who did not reach complete response (CR) on PET/CT after 4 cycles (non-responders) discontinued BV and received the next treatment line. Overall survival (OS) and progression-free survival (PFS) were compared between responders and non-responders.

RESULTS

After a median follow-up of 19.1 months, all consolidation patients were alive and none progressed. Median OS in 23 relapsed patients that did not achieve CR after 4 cycles and continued to the next treatment was 55.0 months, while all those in CR (n = 24) were alive (P = .0120). No statistically significant differences in OS were observed between responders and non-responders with relapsed HL (P = .1072). Median PFS evaluated after 4 BV cycles was significantly longer in responders compared to non-responders (47.9 vs. 1.5 months, P < .0001). Neuropathy and neutropenia were the main toxicities observed.

CONCLUSIONS

HL patients treated with BV for relapse or consolidation who achieved CR by PET-CT after 4 cycles showed improved PFS and OS compared to non-responders. Non-responders treated for relapsed HL who proceeded to the next treatment line demonstrated comparable OS to responders.

摘要

背景

博纳吐单抗-依喜替康（BV）单药治疗在接受高剂量化疗或自体干细胞移植（ASCT）后复发或难治性霍奇金淋巴瘤（HL）的重度预处理患者中显示出高疗效。我们回顾性分析了 BV 治疗 HL 患者的结果，并检查了 PET-CT 在该情况下预测反应的能力。

患者和方法

分析了 49 例接受 BV 治疗复发（71.4%）或 ASCT 后巩固（28.6%）的 HL 患者的记录。在 4 个周期后 PET/CT 未达到完全缓解（CR）的患者（无反应者）停止使用 BV 并接受下一线治疗。比较了 responders 和 non-responders 的总生存期（OS）和无进展生存期（PFS）。

结果

中位随访 19.1 个月后，所有巩固治疗患者均存活且无进展。23 例 4 个周期后未达到 CR 且继续下一线治疗的复发患者的中位 OS 为 55.0 个月，而所有 CR 患者（n=24）均存活（P=0.0120）。在 4 个 BV 周期后达到 CR 的 responders和未达到 CR 的 non-responders 的 OS 无统计学差异（P=0.1072）。4 个 BV 周期后评估的 PFS 在 responders 中明显长于 non-responders（47.9 与 1.5 个月，P<0.0001）。主要毒性反应为神经病变和中性粒细胞减少。